BullFrog AI collaborates with Eleison Pharmaceuticals to enhance oncology data analytics and prepare for a joint conference submission.
Quiver AI Summary
BullFrog AI Holdings, Inc. has announced an update on its collaboration with Eleison Pharmaceuticals, focusing on using AI and machine learning for drug development, specifically in oncology. The partnership has led to the creation of a new data ingestion module, bfPREP™, which successfully converted over 10,000 pages of clinical trial PDFs into a standardized dataset. This innovation allows for efficient analysis of complex clinical data, enabling better patient targeting in clinical trials. Both companies are preparing for a joint submission to an upcoming oncology conference to showcase their findings, and they are also discussing further collaborative opportunities. BullFrog AI aims to demonstrate the effectiveness of its platforms in improving clinical trial efficiencies amidst the industry's need for reduced risk and costs.
Potential Positives
- Collaboration with Eleison Pharmaceuticals highlights BullFrog AI's capabilities in handling complex clinical data, leading to the successful development of a new product, bfPREP™.
- Joint scientific submission planned for an upcoming oncology conference, which may further validate the commercial value of BullFrog AI's AI platforms.
- The partnership is exploring a follow-on contract for additional collaboration work, indicating strong momentum and potential for future revenue growth.
Potential Negatives
- There is reliance on forward-looking statements regarding the company's financial performance and future opportunities, which introduces uncertainty and potential volatility for investors.
- The press release does not provide concrete details on the expected outcomes or results from the collaboration with Eleison, which may raise questions about the effectiveness of their solutions.
- There is an indication that the biopharma sector is under constant pressure to reduce risk and cost, suggesting that BullFrog AI may face challenges in proving its value proposition in a competitive market.
FAQ
What is the purpose of BullFrog AI's collaboration with Eleison Pharmaceuticals?
The collaboration aims to utilize BullFrog AI's technology to enhance drug development for rare cancers.
What does the bfPREP™ module do?
bfPREP™ transforms complex clinical trial data into standardized datasets to facilitate actionable insights for pharmaceutical partners.
How does BullFrog AI ensure data accuracy in analytics?
The company employs a layered approach with automation for repeatable tasks and human reviewers for data accuracy.
What upcoming milestones are planned for the collaboration?
BullFrog AI and Eleison are preparing a joint scientific submission for an oncology conference and discussing a follow-on contract.
What impact does BullFrog AI's technology have on clinical trials?
The technology improves patient targeting and trial efficiency, potentially reducing development costs for pharmaceuticals.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BFRG Insider Trading Activity
$BFRG insiders have traded $BFRG stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $BFRG stock by insiders over the last 6 months:
- VININDER SINGH (Chief Executive Officer) has made 0 purchases and 5 sales selling 79,002 shares for an estimated $117,719.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BFRG Hedge Fund Activity
We have seen 5 institutional investors add shares of $BFRG stock to their portfolio, and 7 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS GROUP AG removed 70,178 shares (-98.2%) from their portfolio in Q2 2025, for an estimated $105,968
- TWO SIGMA SECURITIES, LLC removed 20,701 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $34,156
- VIRTU FINANCIAL LLC removed 20,504 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $30,961
- J.W. COLE ADVISORS, INC. removed 17,000 shares (-43.5%) from their portfolio in Q2 2025, for an estimated $25,670
- GEODE CAPITAL MANAGEMENT, LLC added 1,775 shares (+3.3%) to their portfolio in Q2 2025, for an estimated $2,680
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 1,064 shares (+7.7%) to their portfolio in Q2 2025, for an estimated $1,606
- TOWER RESEARCH CAPITAL LLC (TRC) added 1,033 shares (+80.3%) to their portfolio in Q2 2025, for an estimated $1,559
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Joint oncology conference submission planned and follow-on contract discussion underway
Validates BullFrog AI’s enterprise-grade platform strategy, combining automation and human-in-the-loop oversight for scalable, trustworthy analytics
GAITHERSBURG, Md., Sept. 08, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today provided an update on its collaboration with Eleison Pharmaceuticals Inc. (“Eleison”), a Phase 3 oncology company focused on novel chemotherapeutic treatments for rare cancers.
To support this collaboration, BullFrog AI developed a new data ingestion module, purpose-built to handle the scale and complexity of Eleison’s historical clinical data. Originally created to convert more than 10,000 pages of clinical trial PDFs into an OMOP-standardized dataset for Eleison, the module proved so effective that it has since become a standalone commercial offering of BullFrog AI called bfPREP ™ .
“Our bfPREP ™ module turns legacy and siloed clinical trial data into a strategic asset,” said Vin Singh, CEO of BullFrog AI. “In the case of Eleison, we were dealing with a vast amount of complex clinical documentation, the kind of data that typically slows down or derails analytics efforts. With our purpose-built, proprietary technology, we were able to ingest, clean, and standardize that data at scale, transforming it into a foundation for actionable insights. It’s a clear demonstration of how our enterprise-grade platforms can handle the volume, variability, and nuance of real-world clinical datasets, positioning BullFrog AI as a highly capable and trusted partner to the pharmaceutical industry.”
Scalable AI-Driven Value Creation
Following ingestion, BullFrog AI applied feature engineering and AI-enhanced curation to extend the dataset, categorizing diseases, medications, lesion descriptors, and normalizing free text into structured fields. Using a layered approach, where automation handles repeatable tasks and human reviewers ensure accuracy, the Company was able to rapidly scale data preparation while maintaining the integrity and nuance required for clinical decision-making.
The structured dataset was then deployed into bfLEAP ® , BullFrog AI’s core analytics engine, to identify data-driven patient subgroups ahead of randomization. These insights may inform both trial design and market positioning, as they illuminate patient segments most likely to benefit from Eleison’s therapies.
“This initiative demonstrates how bfPREP ™ and bfLEAP ® can improve patient targeting and create meaningful insights to accelerate trial efficiency for pharmaceutical partners. We view this as a strong proof point for the broader application of our platforms across the drug development landscape,” added Mr. Singh.
“We’ve been impressed by BullFrog’s rigor and responsiveness and are extremely pleased with the collaboration to date,” said Matt Cromie, MS, VP Clinical Development at Eleison. “We look forward to continuing our efforts together.”
Upcoming Milestones and Expansion Potential
Encouraged by the progress, BullFrog AI and Eleison are preparing a joint scientific submission to an upcoming oncology conference, which management believes will further validate the commercial value of the Company’s AI platforms. In addition, the two companies are exploring further collaboration through a second contract for additional collaboration work.
“Every milestone in this collaboration strengthens our case for broader adoption of BullFrog AI solutions across the industry,” Mr. Singh added. “With the biopharma sector under constant pressure to reduce risk and cost in clinical development, we see significant investor upside in demonstrating that our platforms can deliver both scientific and financial impact.”
About BullFrog AI
BullFrog AI leverages Artificial Intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP ® platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials.
For more information visit BullFrog AI at: https://bullfrogai.com
About Eleison Pharmaceuticals
Eleison’s mission is to acquire and develop drug candidates with existing and significant safety and efficacy data, with the goal of obtaining regulatory approval and commercializing new therapeutics for patients with life-threatening cancers. In addition to its glufosfamide program, the company has two other programs in late-stage clinical development: ILC for small cell lung cancer and pediatric osteosarcoma, and DBD for brain cancers. Eleison has entered development and marketing partnerships with leading pharmaceutical companies in China, South Korea, and Israel. Founded in 2009, Eleison is headquartered in Princeton, NJ.
For more information, visit www.eleison-pharma.com .
Safe Harbor Statement
This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," “could,” “will,” "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; our and our partners’ ability to market and sell our offerings and services, including BullFrog Data Networks™; our ability to maintain compliance with Nasdaq listing rules; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
[email protected]
